For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and the formulated version represents a true advancement . These novel therapies stabilize the transthyretin protein, preventing its damaging build-up and alleviating the impact of the disease . People are now reporting benef